GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Antengene Corp Ltd (FRA:722) » Definitions » Short Percentage of Float

Antengene (FRA:722) Short Percentage of Float


View and export this data going back to 2021. Start your Free Trial

What is Antengene Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Antengene's Short Percentage of Float

For the Biotechnology subindustry, Antengene's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Antengene's Short Percentage of Float Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Antengene's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Antengene's Short Percentage of Float falls into.


;
;

Antengene Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Antengene Corp Ltd (FRA:722) » Definitions » Short Percentage of Float
Comparable Companies
HKSE:02181 HKSE:02487 HKSE:02563 HKSE:06978 HKSE:02566 HKSE:03681 HKSE:01875 HKSE:02137 HKSE:01521 HKSE:02509 VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
06996:Hong Kong 722:Germany
Address
1065 West Zhongshan Road, Suites 1206-1209, Block B, Zhongshan SOHO Plaza, Changning District, Shanghai, CHN
Website
https://www.antengene.com
Antengene Corp Ltd is a clinical-stage biopharmaceutical company focused on oncology medicines. The company produces drugs such as selinexor, eltanexor, verdinexor, and other products. It also engages in the discovery, development, manufacturing, and commercialization of first-in-class therapeutics for the treatment of hematologic malignancies and solid tumors. Geographically it operates in Chinese Mainland, Hong Kong, Macao and Taiwan and Overseas.

Antengene Headlines

No Headlines